You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥控股(01099.HK)年度歸母淨利增長14.95%至71.87億元 末期息0.69元
格隆匯 03-22 07:05

格隆匯 3 月 22日丨國藥控股(01099.HK)發佈截至2020年12月31日止年度業績公吿,報吿期間,集團實現營業收入人民幣4564.15億元,同比增長7.32%;公司母公司持有者應占溢利人民幣71.87億元,同比增長14.95%;公司基本每股盈利人民幣2.31元,比上年同期增長9.48%;建議派發年度末期股息每股人民幣0.69元(含税)。

報吿期間,集團收入同比增加7.32%,主要由於集團醫藥分銷業務、醫藥零售業務及醫療器械業務收入的增長,且集團收入增長超過中國醫藥市場發展的平均水平。醫藥分銷分部方面,報吿期間集團醫藥分銷收入為人民幣3482.94億元,佔集團總收入比例為74.18%,同比增加3.25%,主要是由於集團醫藥分銷業務發展勢態良好及分銷網絡進一步擴展。

醫藥零售分部方面,報吿期間集團醫藥零售收入為人民幣241.64億元,佔集團總收入比例為5.15%,同比增加22.02%,增長主要是由於零售藥品市場增長。醫療器械分部方面,報吿期間集團醫療器械收入為人民幣894.02億元,佔集團總收入比例為19.04%,同比增加29.02%,增長主要是由於集團醫療器械業務的收購擴張及業務增長。此外,其他業務分部方面,報吿期間集團其他業務收入為人民幣76.52億元,同比增加51.91%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account